Home Cart Sign in  
Chemical Structure| 485-72-3 Chemical Structure| 485-72-3

Structure of Formononetin
CAS No.: 485-72-3

Chemical Structure| 485-72-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Formononetin can act as an agonist of aryl hydrocarbon receptor (EC50 = 130 nM) and has prevention of breast cancer, prostate cancer and colon cancer. Formononetin could be extracted from the bark of Ononis natrix L..

Synonyms: Biochanin B; Flavosil; Formononetol Formononetin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Formononetin

CAS No. :485-72-3
Formula : C16H12O4
M.W : 268.26
SMILES Code : O=C1C(C2=CC=C(OC)C=C2)=COC3=C1C=CC(O)=C3
Synonyms :
Biochanin B; Flavosil; Formononetol Formononetin
MDL No. :MFCD00016948
InChI Key :HKQYGTCOTHHOMP-UHFFFAOYSA-N
Pubchem ID :5280378

Safety of Formononetin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HCC827 OR 10μM 24 hours Formononetin significantly inhibited the cell viability of HCC827 OR cells. J Exp Clin Cancer Res. 2020 Apr 10;39(1):62.
H1299 10μM 24 hours Formononetin significantly inhibited the cell viability of H1299 cells. J Exp Clin Cancer Res. 2020 Apr 10;39(1):62.
A549 10μM 24 hours Formononetin significantly inhibited the cell viability of A549 cells. J Exp Clin Cancer Res. 2020 Apr 10;39(1):62.
H1975 10μM 24 hours Formononetin significantly inhibited the cell viability of H1975 cells. J Exp Clin Cancer Res. 2020 Apr 10;39(1):62.
H3255 10μM 24 hours Formononetin significantly inhibited the cell viability of H3255 cells. J Exp Clin Cancer Res. 2020 Apr 10;39(1):62.
Human umbilical vein endothelial cells 10 μM 24 hours FN stabilizes NRF2 levels in HUVECs, protecting cells from oxaliplatin-induced damage. Redox Biol. 2020 Sep;36:101677.
Mouse dorsal root ganglion neurons 10 μM 24 hours FN protects DRG neurons from oxaliplatin-induced damage by activating the NRF2-GSTP1 axis. Redox Biol. 2020 Sep;36:101677.
ND7/23 neuron cells 10 μM 24 hours FN protects neurons from oxaliplatin-induced damage by activating the NRF2 pathway, increasing NRF2 protein levels and reducing ROS production. Redox Biol. 2020 Sep;36:101677.
BUMPT cells 25 mg/kg 3 days Induced PRDM16 expression, peaking at 25 mg kg−1 Adv Sci (Weinh). 2024 Feb;11(7):e2306704.
Human aortic smooth muscle cells (HASMCs) 1-5 μM 24 hours Inhibited oxLDL-induced foam cell formation and reduced lipid droplet accumulation Theranostics. 2020 Jan 1;10(3):1090-1106.
Peritoneal macrophages (PMs) 1-5 μM 24 hours Inhibited oxLDL-induced foam cell formation and reduced lipid droplet accumulation Theranostics. 2020 Jan 1;10(3):1090-1106.
Hep3B cells 20μM, 40μM Formononetin treatment inhibited the binding of SLUG to the promoter of E-cadherin, upregulated the expression level of epithelial markers (E-cadherin, cytokeratin, and occludin), and downregulated the expression level of mesenchymal markers (Vimentin, N-cadherin, and myosin). Theranostics. 2019 Jan 1;9(2):573-587.
PLC-PRF-5 cells 20μM, 40μM Formononetin treatment inhibited the binding of SLUG to the promoter of E-cadherin, upregulated the expression level of epithelial markers (E-cadherin, cytokeratin, and occludin), and downregulated the expression level of mesenchymal markers (Vimentin, N-cadherin, and myosin). Theranostics. 2019 Jan 1;9(2):573-587.
BUMPT cells 20 µM 30 minutes Formononetin significantly reduced I/R-stimulated BUMPT cell apoptosis and inhibited the activation of p38MAPK and JNK by upregulating the PRDM16/S100A6/PKC-η/ROS signaling pathways. MedComm (2020). 2024 Sep 21;5(10):e737.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Xenograft model Intraperitoneal injection 10 mg/kg Once daily until the endpoint of the experiment Formononetin significantly inhibited the growth of xenograft tumors, including HCC827, H3255, H1975, A549, and H1299-derived tumors. J Exp Clin Cancer Res. 2020 Apr 10;39(1):62.
C57BL/6 male mice Oxaliplatin-induced peripheral neuropathy model Intraperitoneal injection 10.0 mg/kg Daily injections for two cycles (5 days of injection and 5 days of rest per cycle) FN alleviates mechanical and cold sensitivity in mice by activating the NRF2 signaling pathway and reduces morphological damage in DRG neurons. Redox Biol. 2020 Sep;36:101677.
ApoE-deficient mice High-fat diet-induced atherosclerosis model Oral 10 mg/kg/day Once daily for 16 weeks Formononetin significantly reduced atherosclerotic lesion size, enhanced plaque stability, reduced macrophage accumulation and calcification Theranostics. 2020 Jan 1;10(3):1090-1106.
Db/db diabetic mice Diabetic kidney disease model Intragastric administration 25 mg/kg Once a day for four weeks Attenuated renal fibrosis, MAPK activation, and TGF-β1 expression Adv Sci (Weinh). 2024 Feb;11(7):e2306704.
Nude mice Hepatocellular carcinoma xenograft model Subcutaneous injection 100 mg/kg Every 2 days for 15 days Formononetin treatment inhibited tumor volume, fluorescence intensity, tumor weight, and the formation of pulmonary metastatic nodules. IHC analysis showed that Formononetin treatment decreased the expression of SLUG, Vimentin, and Ki67, and increased the expression of E-cadherin. Theranostics. 2019 Jan 1;9(2):573-587.
C57BL/6J mice Cecal ligation and puncture (CLP)-induced sepsis model Tail vein injection 20 mg/kg Single dose, observed for 18 hours To evaluate the protective effect of Formononetin/PLGA on sepsis-induced multi-organ injury. Results showed that Formononetin/PLGA inhibited ferroptosis by upregulating the PRDM16/NRF2/GPX4 axis, alleviating sepsis-induced kidney injury and other organ injuries. Redox Biol. 2024 Dec;78:103417.
Mice Ischemia/reperfusion (I/R) and cisplatin-induced acute kidney injury (AKI) model Oral administration 25 mg/kg 3 consecutive days Formononetin significantly ameliorated the progression of I/R- and cisplatin-triggered AKI in mice by regulating the PRDM16/S100A6/PKC-η/ROS/p38MAPK and JNK axes. MedComm (2020). 2024 Sep 21;5(10):e737.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02174666 Osteopenia Os... More >>teoporosis Less << Not Applicable Unknown September 2016 Denmark ... More >> Aarhus University Hospital Aarhus, Central Jutland Region, Denmark, 8000 Less <<
NCT01497977 Low Serum Lipid Levels Phase 4 Completed - Serbia ... More >> Ultramedica Clinic, American Medical Academy Belgrade, Serbia, 11000 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.73mL

0.75mL

0.37mL

18.64mL

3.73mL

1.86mL

37.28mL

7.46mL

3.73mL

References

 

Historical Records

Categories